1HARMS A E. Process for preparation of azcpanylfluoroqui- nolonecarboxylatcs from chloroquinolincs and azepan derivatives and their use as antibacterials:US ,2008/176834AI [ P]. 2008 -07 -24.
2HARMS A E. Process for preparation of fluoroheterocycloquinolones by reaction of difluoroquinolones with cyclic amines: WO,2008/045673 A2[ P]. 2008 -04 - 17.
3WARD K W,LEPAGE J F,DRIOT J Y. Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use [J]. J Ocu Pharm Ther,2007,23(3) :243 -256.
4HAAS W,PILLAR C M,ZURENO G E,et al. Besifloxacin,a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic baeteria[ J ]. Antimierob Agents Chemother, 2009,53 ( 8 ) : 3552 - 3560.
5KARPECKI P,DEPAOLIS M, HUNTER J A,et al. Besifloxacin ophthalmic suspension 0. 6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double- masked, vehicle-controlled, S-day efficacy and safety study [J]. Clin Ther,2009,31 (3) :514 -526.
6TEPEDINO M E, HELLER W H, USNER D W, et al. Phase III efficacy and safety study of bcsifloxacin ophthalmic suspension 0.6% in the trealrnent of bactcdal conjunctivitis[ J]. Curr Med Res Opin,2009,25(5) :1159 -1169.
2Chang MH, Fung HB.Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjtmctivitis[J]. Clin Ther,2010,32(3) :454.
3Haas W, Pillar CM, Hesje CK, et al. Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae[J]. JAntimicrobChemother, 201 0, 65 (7) : 1 441.
4Zhang JZ, Cavet ME, Ward KW. Anti-inflammatory ef- fects of besifloxacin, a novel fluoroquinolone, in primary human corneal epithelial cells[J]. Curr Eye Res, 2008, 33(11):923.
5Sanders ME, Norcross EW, Moore QC 3rd, et al. Efficacy of besifloxacin in a rabbit model of methicillin-resistant staphylococcus aureus keratitis [J]. Cornea, 2009,28 (9) : 1 055.
6Sanders ME, Moore QC 3rd, Norcross EW, et al. Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis[J]. J Ocul Pharmacol Ther, 2010,26(2) : 193.
7Cambau E, Matrat S, Pan XS, et al. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli [J]. J.4ntimicrob Chemother, 2009,63 (3) : 443.
8Torkildsen G, Proksch JW, Shapiro A, et al. Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration [J]. Clin Ophthalmol, 2010,26(4) : 331.
9Haas W, Pillar CM, Zurenko GE, et al. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria[J].Antimicrob Agents Chemother, 2009,53(8) : 3 552.
10Karpecki PM, Morris TW, Zhang JZ. Besifloxacin: a novel anti-infective for the treatment of bacterial conjunc tivitis[J]. Clin Ophthalmol, 2010,26(4) : 215.
